Current - 6 hours ago

* Home

* About

* Portfolio

* Meet the Team

* News

* Contact

* Investor Portal

* info@chv.vc

* 129 South Street, 4th Floor, Boston, MA 02111

*

Home / News

News & Updates

Featured Story

Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors

* June 26, 2024

* -

* Epitel

Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

* May 14, 2024

* -

* Brixton Biosciences

Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection

* April 23, 2024

* -

* Epitel

Select a Company Allegro Diagnostics (1) Aria CV (5) AtaCor Medical (4) Augmenix (1) Biocius (1) BioTrove (1) Conformal (13) GI Dynamics (1) Sera Prognostics (26) nVision (1) Maxwell Health (1) Vortex Medical (1) Novazyme Pharmaceuticals (1) Saphena Medical (3) Brixton Biosciences (2) PanTher Therapeutics (5) Instylla Inc. (3) Catalyst Health Ventures (2) Epitel (4) Avive (2) Rejoni (1)

The Latest

Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors

* June 26, 2024

* -

* Epitel

Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

* May 14, 2024

* -

* Brixton Biosciences

Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection

* April 23, 2024

* -

* Epitel

Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in Communities Nationwide

* April 18, 2024

* -

* Avive

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

* February 27, 2024

* -

* Aria CV

Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success

* December 6, 2023

* -

* Sera Prognostics

BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA

* October 26, 2023

* -

* Brixton Biosciences

Conformal Medical Raises $35 Million in Oversubscribed Series D Round

* June 6, 2023

* -

* Conformal

Show More

Let’s Connect.

Contact Us

Sitemap

* Home

* About

* Portfolio

* Meet the Team

* News

* Contact

* Investor Portal

About

Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs.

Contact

* info@chv.vc

Boston Web Design by GoingClear